Evidence map›Paper›PMID 37407550›Full record

ArticleBlood cancer journal2023

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.

Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, Duane Hassane, Timour Baslan, Daniel T Gildea, Samuel Haddox, Tak Lee, H Moses Murdock, Caroline Sheridan and 16 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Franck Rapaport *Human Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenneth Seier *Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yaseswini Neelamraju *Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Duane HassaneDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Timour BaslanCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniel T GildeaDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Samuel HaddoxDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Tak LeeDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
H Moses MurdockDivision of Hematology and Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-4098-8968
Caroline SheridanDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Alexis ThurmondDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Ling WangDivision of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Martin CarrollDivision of Hematology and Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Larry D CripeSimon Cancer Center, Indiana University, Indianapolis, IN, USA.
Hugo FernandezDepartment of Malignant Hematology & Cellular Therapy, Moffitt Cancer Center, Tampa, FL, USA.
Christopher E MasonDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Elisabeth PaiettaMontefiore Medical Center, Bronx, NY, USA.
Gail J RobozWeill Cornell Medicine and The New York Presbyterian Hospital, New York, NY, USA.
Zhuoxin SunDana-Farber Cancer Institute, Boston, MA, USA.
Martin S TallmanMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Yanming ZhangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mithat Gönen *Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ross Levine *Human Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7884-1905
Ari M Melnick *Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-8074-2287
Maria KleppeHuman Oncology and Pathogenesis Program, Molecular Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Francine E Garrett-BakelmanDepartment of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA. fg5q@virginia.edu.ORCID http://orcid.org/0000-0002-4771-628X

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Summer Research Experience in Cancer(SuRE-C)R25CA206972 · NCI · UNIVERSITY OF VIRGINIA · PI ADRIAN J HALME, Hui Zong · 2017 to 2026
$2.0M
NCI NIH HHS P30 CA044579NCI NIH HHS R25 CA206972
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37407550
PMCPMC10322919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.